Zetiq Completes Cancer Diagnosis Kit

Globes

By Gali Weinreb

Israeli start-up Zetiq Technologies Ltd., a subsidiary of Bio-Light Israeli Life Sciences Investments Ltd. (TASE:BOLT), has completed development of its diagnostic kit for cancerous cells, and plans to begin marketing them immediately to research institutes. The company does not need US Food and Drug Administration (FDA) approval for this purpose.

Research institutes are not Zetiq’s primary target market. Although the company is currently seeking distributors, it does not expect major sales from this sector. The company plans to continue development of its kits for both diagnostic and drug development uses.